Crispr Therapeutics (NASDAQ:CRSP) had its price objective increased by Canaccord Genuity from $72.00 to $80.00 in a research report report published on Wednesday, November 20th, The Fly reports. The firm currently has a positive rating on the stock.
CRSP has been the topic of several other reports. William Blair raised shares of Crispr Therapeutics from a market perform rating to an outperform rating in a report on Tuesday, November 19th. Zacks Investment Research cut shares of Crispr Therapeutics from a hold rating to a sell rating in a report on Monday, September 30th. Jefferies Financial Group started coverage on shares of Crispr Therapeutics in a report on Thursday, August 1st. They set a buy rating and a $64.00 target price on the stock. Wells Fargo & Co reissued a buy rating on shares of Crispr Therapeutics in a report on Tuesday, November 19th. Finally, BTIG Research increased their price objective on shares of Crispr Therapeutics from $51.00 to $59.00 and gave the stock a positive rating in a report on Tuesday, July 30th. Two research analysts have rated the stock with a sell rating, two have issued a hold rating and fourteen have given a buy rating to the company. The stock presently has an average rating of Buy and an average price target of $69.54.
Shares of CRSP stock traded up $0.97 on Wednesday, hitting $66.33. The stock had a trading volume of 920,983 shares, compared to its average volume of 713,132. The firm has a market capitalization of $3.61 billion, a price-to-earnings ratio of -19.28 and a beta of 3.30. The stock’s 50 day moving average is $60.48 and its 200-day moving average is $48.87. The company has a debt-to-equity ratio of 0.06, a quick ratio of 8.32 and a current ratio of 8.32. Crispr Therapeutics has a 52-week low of $22.22 and a 52-week high of $74.00.
Crispr Therapeutics (NASDAQ:CRSP) last posted its quarterly earnings results on Monday, October 28th. The company reported $2.40 earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.95) by $3.35. The firm had revenue of $211.93 million for the quarter, compared to analysts’ expectations of $6.32 million. Crispr Therapeutics had a negative net margin of 5.30% and a negative return on equity of 2.60%. Equities analysts expect that Crispr Therapeutics will post 0.65 earnings per share for the current year.
In related news, Director Pablo J. Cagnoni sold 7,500 shares of the company’s stock in a transaction dated Tuesday, November 12th. The shares were sold at an average price of $55.00, for a total transaction of $412,500.00. Following the completion of the transaction, the director now owns 7,500 shares in the company, valued at approximately $412,500. The transaction was disclosed in a legal filing with the SEC, which can be accessed through the SEC website. Also, President Rodger Novak sold 33,618 shares of the company’s stock in a transaction dated Tuesday, November 19th. The stock was sold at an average price of $70.00, for a total transaction of $2,353,260.00. Following the transaction, the president now owns 33,618 shares of the company’s stock, valued at approximately $2,353,260. The disclosure for this sale can be found here. In the last 90 days, insiders have sold 56,118 shares of company stock valued at $3,620,760. Insiders own 21.40% of the company’s stock.
A number of hedge funds have recently added to or reduced their stakes in the business. Benjamin Edwards Inc. raised its holdings in Crispr Therapeutics by 96.4% in the 2nd quarter. Benjamin Edwards Inc. now owns 546 shares of the company’s stock valued at $26,000 after acquiring an additional 268 shares during the last quarter. Zurcher Kantonalbank Zurich Cantonalbank raised its holdings in Crispr Therapeutics by 13.6% in the 3rd quarter. Zurcher Kantonalbank Zurich Cantonalbank now owns 2,870 shares of the company’s stock valued at $118,000 after acquiring an additional 343 shares during the last quarter. Traynor Capital Management Inc. raised its holdings in Crispr Therapeutics by 5.8% in the 3rd quarter. Traynor Capital Management Inc. now owns 6,845 shares of the company’s stock valued at $280,000 after acquiring an additional 375 shares during the last quarter. Commonwealth Equity Services LLC raised its holdings in Crispr Therapeutics by 2.2% in the 3rd quarter. Commonwealth Equity Services LLC now owns 18,201 shares of the company’s stock valued at $746,000 after acquiring an additional 386 shares during the last quarter. Finally, D. E. Shaw & Co. Inc. raised its holdings in Crispr Therapeutics by 7.1% in the 2nd quarter. D. E. Shaw & Co. Inc. now owns 7,019 shares of the company’s stock valued at $331,000 after acquiring an additional 467 shares during the last quarter. Institutional investors own 49.82% of the company’s stock.
Crispr Therapeutics Company Profile
CRISPR Therapeutics AG, a gene editing company, focuses on developing transformative gene-based medicines for the treatment of serious human diseases using its regularly interspaced short palindromic repeats associated protein-9 (CRISPR/Cas9) gene-editing platform in Switzerland. Its lead product candidate is CTX001, an ex vivo CRISPR gene-edited therapy for treating patients suffering from dependent beta thalassemia or severe sickle cell disease in which a patient's hematopoietic stem cells are engineered to produce high levels of fetal hemoglobin in red blood cells.
See Also: Different Types of Derivatives
Receive News & Ratings for Crispr Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Crispr Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.